Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental drug aims to protect kidneys in inflammatory diseases

NCT ID NCT06419205

Not yet recruiting Disease control Sponsor: Akebia Therapeutics Source: ClinicalTrials.gov ↗

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study tests an experimental drug called ADX-097 in people aged 16 and older with three kidney conditions: IgA nephropathy, lupus nephritis, and C3 glomerulopathy. The drug is given as an injection under the skin and is designed to reduce inflammation and protein leakage in the urine. Researchers will monitor safety, how the drug moves through the body, and whether it helps preserve kidney function over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ADX-097
What this could lead to
If successful, ADX-097 could offer a new treatment option to slow kidney damage and reduce protein leakage in people with certain inflammatory kidney diseases.
What could go wrong
This is an early Phase 2 study with only 30 participants, so results may not apply to everyone. The drug may cause side effects or fail to improve kidney function.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for C3 (COMPLEMENT COMPONENT 3) GLOMERULOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

complement 3 glomerulopathy complement component 3 deficiency IgA glomerulonephritis lupus nephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

C3 (COMPLEMENT COMPONENT 3) GLOMERULOPATHY IGA NEPHROPATHY LUPUS NEPHRITIS (LN)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.